Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2551 to 2600 of 3761 results for treatment

  1. Laparoscopic mobilisation of the greater omentum for breast reconstruction (HTG162)

    Evidence-based recommendations on laparoscopic mobilisation of the greater omentum for breast reconstruction. This involves removing the fatty tissue using special instruments through small cuts in the abdomen.

  2. Mosunetuzumab with lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6655]

    Awaiting development Reference number: GID-TA11867 Expected publication date: TBC

  3. Subcutaneous mosunetuzumab for treating relapsed or refractory follicular lymphoma after 2 or more treatments TSID 12081

    Awaiting development Reference number: GID-TA11705 Expected publication date: TBC

  4. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for vaginal vault prolapse

    prolapse can cause discomfort and problems with urination. There are some treatment options that don't involve surgery that NICE says...

  5. Evidence summaries: new medicines – Integrated process statement (PMG11)

    This integrated process statement has been produced to explain how 'Evidence summaries: new medicines' (ESNMs) are developed. It provides an overview of the key process principles and describes all stages of the development of ESNMs

  6. Laparoscopic prostatectomy for benign prostatic obstruction (HTG176)

    Evidence-based recommendations on laparoscopic prostatectomy for benign prostatic obstruction. This involves removing the prostate through small cuts in the abdomen, using a fine telescope to see inside the body (keyhole surgery).

  7. Percutaneous vertebroplasty (HTG3)

    Evidence-based recommendations on percutaneous vertebroplasty for spinal metastases. This involves injecting a special bone cement into the spine to relieve pain and stabilise the fracture site.

  8. Developing NICE guidelines: the manual (PMG20)

    This manual explains the processes and methods used to develop and update NICE guidelines, the guidance that NICE develops covering topics across clinical care (in primary, secondary and community care settings), social care and public health. For more information on the other types of NICE guidance and advice (including technology appraisal guidance), see about NICE

  9. Delirium: prevention, diagnosis and management in hospital and long-term care (CG103)

    This guideline covers diagnosing and treating delirium in people aged 18 and over in hospital and in long-term residential care or a nursing home. It also covers identifying people at risk of developing delirium in these settings and preventing onset. It aims to improve diagnosis of delirium and reduce hospital stays and complications.

  10. ColonFlag for identifying people at risk of colorectal cancer (MIB142)

    NICE has developed a medtech innovation briefing (MIB) on ColonFlag for identifying people at risk of colorectal cancer .

  11. Learning disability: identifying and managing mental health problems (QS142)

    This quality standard covers the prevention, assessment and management of mental health problems in people with learning disabilities in all settings (including health, social care, education, and forensic and criminal justice). It also covers family members, carers and care workers.

  12. GreenLight XPS for treating benign prostatic hyperplasia (HTG650)

    Evidence-based recommendations on GreenLight XPS for treating benign prostatic hyperplasia.

  13. Woundchek Protease Status for assessing elevated protease status in chronic wounds (MIB83)

    NICE has developed a medtech innovation briefing (MIB) on the Woundchek Protease Status for assessing elevated protease status in chronic wounds .

  14. Percutaneous endoscopic laser thoracic discectomy (HTG34)

    Evidence-based recommendations on percutaneous endoscopic laser thoracic discectomy. This involves using a laser to heat and destroy some of the inside of the disc and shrink the part that is sticking out.

  15. Balloon dilatation with or without stenting for pulmonary artery or non-valvar right ventricular outflow tract obstruction in children (HTG47)

    Evidence-based recommendations on balloon dilatation with or without stenting for pulmonary artery or non-valvar right ventricular outflow tract obstruction in children. This involves using a balloon to widen the narrow area of the heart to let blood flow through it more easily.

  16. Familial breast cancer. Patient decision aid on taking a medicine to reduce the chance of developing breast cancer for postmenopausal women at moderately increased risk

    lower baseline risk than this, and what this means about the effects of treatment. Remember that no-one can say what will happen to any...

  17. Percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices (HTG251)

    Evidence-based recommendations on percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices. This involves using a special cutting device to remove excess debris inside diseased blood vessels.

  18. Therapeutic hypothermia with intracorporeal temperature monitoring for hypoxic perinatal brain injury (HTG221)

    Evidence-based recommendations on therapeutic hypothermia with intracorporeal temperature monitoring for hypoxic perinatal brain injury. This involves cooling either the baby's head or whole body to prevent brain damage.

  19. Types of recommendation NICE can make

    NICE makes 4 types of recommendation that allow us to produce clear, directive, actionable guidance that is easy to understand and put into practice.

  20. PLASMA system with button electrode for electrovaporisation of the prostate (MIB274)

    NICE has developed a medtech innovation briefing (MIB) on PLASMA system with button electrode for electrovaporisation of the prostate .

  21. Peptest for diagnosing gastro‑oesophageal reflux (MIB31)

    NICE has developed a medtech innovation briefing (MIB) on Peptest for diagnosing gastro-oesophageal reflux

  22. VA ECMO for postcardiotomy cardiogenic shock in adults (HTG762)

    Evidence-based recommendations on venoarterial extracorporeal membrane oxygenation (VA ECMO) for postcardiotomy cardiogenic shock in adults. This involves using an artificial lung to oxygenate the blood outside the body.

  23. Transient loss of consciousness ('blackouts') in over 16s (QS71)

    This quality standard covers assessing, diagnosing and referring people (aged 16 and over) who have had a transient loss of consciousness (often called a blackout). It describes high-quality care in priority areas for improvement.

  24. Diabetes in pregnancy (QS109)

    This quality standard covers managing diabetes and its complications in women who are planning a pregnancy or are already pregnant. It includes care for women with pre-existing diabetes before and during pregnancy, and diagnosis and management of gestational diabetes. It describes high-quality care in priority areas for improvement.

  25. Hand allotransplantation (HTG254)

    Evidence-based recommendations on hand transplant surgery (allotransplantation). This involves transplanting a hand from a recently deceased donor onto the amputated stump.

  26. Transcatheter endovascular closure of perimembranous ventricular septal defect (HTG213)

    Evidence-based recommendations on transcatheter endovascular closure of perimembranous ventricular septal defect. This involves inserting a small blocking device (called an occluder) into the heart.

  27. Laser-assisted cerebral vascular anastomosis without temporary arterial occlusion (HTG161)

    Evidence-based recommendations on laser-assisted cerebral vascular anastomosis without temporary arterial occlusion. This involves using a special laser device to create a bypass without the need to temporarily interrupt the blood flow to the brain.

  28. Type 2 diabetes in adults. Patient decision aid on type 2 diabetes: agreeing my blood glucose (HbA1c) target

    2 diabetes find their HbA1c increases over time, even with treatment. That's why treatments may need to be changed as part...

  29. Endoscopic mastectomy and endoscopic wide local excision for breast cancer (HTG188)

    Evidence-based recommendations on endoscopic mastectomy and endoscopic wide local excision for breast cancer. This involves removing part or all of the breast using special instruments inserted through small cuts in the skin (keyhole surgery).

  30. Fetal monitoring in labour (NG229)

    This guideline covers methods for monitoring the wellbeing of the baby during labour. It includes risk assessment to determine the appropriate level of fetal monitoring, using clinical assessment in addition to fetal monitoring, and interpreting and acting on monitoring findings.

  31. Cryotherapy for the treatment of liver metastases (IPG369)

    Interventional procedures, IPG369 - Issued: December 2010 --> We have moved interventional procedures guidance 369 to become HealthTech guidance 241. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  32. Rituximab for the treatment of follicular lymphoma (TA110)

    This guidance has been updated and replaced by NICE technology appraisal guidance 243.

  33. Golimumab for the treatment of ankylosing spondylitis (TA233)

    This guidance has been updated and replaced by NICE technology appraisal guidance 383.

  34. Abatacept for the treatment of rheumatoid arthritis (TA141)

    This appraisal has been updated and replaced by NICE technology appraisal guidance 195.

  35. Tocilizumab for the treatment of rheumatoid arthritis (TA198)

    This guidance has been updated and replaced by NICE technology appraisal guidance 247.

  36. Adalimumab for the treatment of psoriatic arthritis (TA125)

    This guidance has been updated and replaced by NICE technology appraisal guidance 199.

  37. Rituximab for the treatment of rheumatoid arthritis (TA126)

    This guidance has been updated and replaced by NICE technology appraisal guidance 195.

  38. Taxanes for the treatment of breast cancer (TA30)

    This guidance has been replaced by NICE guideline CG81.

  39. Taxanes for the treatment of breast cancer (TA6)

    This guidance has been replaced by NICE technology appraisal guidance 30 [Replaced by NICE guideline CG81].

  40. Thousands living with lupus offered hope from twice-yearly infusion

    NICE approves breakthrough combination treatment that restores normal kidney function in almost half of patients with lupus nephritis.

  41. CytoSorb for reducing risk of bleeding during cardiac surgery (MIB249)

    NICE has developed a medtech innovation briefing (MIB) on CytoSorb for reducing risk of bleeding during cardiac surgery .

  42. New pharmaceutical treatments for non-Alzheimer dementias [ID380]

    Discontinued Reference number: GID-TAG369

  43. Safe midwifery staffing for maternity settings (NG4)

    This guideline covers safe midwifery staffing in all maternity settings, including at home, in the community, in day assessment units, in obstetric units, and in units led by midwives (both alongside hospitals and free-standing). It aims to improve maternity care by giving advice on monitoring staffing levels and actions to take if there are not enough midwives to meet the needs of women and babies in the service.

  44. Path Finder for freezing of gait in people with Parkinson's disease (MIB170)

    NICE has developed a medtech innovation briefing (MIB) on Path Finder for freezing of gait in people with Parkinson’s disease .

  45. Tests in secondary care to identify people at high risk of ovarian cancer (HTG453)

    Evidence-based recommendations on tests in secondary care to identify people at high risk of ovarian cancer. The tests are the IOTA ADNEX model, Overa (MIA2G), RMI I (at thresholds other than 250), ROMA and IOTA Simple Rules.

  46. Elranatamab for treating relapsed or refractory multiple myeloma after treatments including anti-CD38 antibody and lenalidomide therapy [ID6591]

    Awaiting development Reference number: GID-TA11753 Expected publication date: TBC

  47. Flu treatment - zanamivir, amantadine and oseltamivir (TA58)

    This guidance has been updated and replaced by NICE technology appraisal guidance 168.

  48. Molecular testing strategies for Lynch syndrome in people with colorectal cancer (HTG430)

    Evidence-based recommendations on using immunohistochemistry or microsatellite instability testing to guide further testing for Lynch syndrome in people with colorectal cancer.